Fibrates and statins have been widely used in clinical practice to reduce triglyceride and cholesterol levels, respectively. These drugs are becoming more beneficial in modern society where the patients of high fat diet-associated common diseases are increasing. Though synergistic clinical benefits of combination therapy with fibrates and statins have been reported, [1] [2] [3] [4] the problem of these drugs especially in combination therapy is the risk of rhabdomyolysis. 5, 6) The biochemical basis for the primary fibrate and/or statin-induced rhabdomyosysis is not well understood. 7, 8) We previously reported that fibrates rapidly induce pyruvate dehydrogenase kinase 4 (PDK4) mRNA in various tissues of mice. 9) Among the tissues examined, the induction of the mRNA in the skeletal muscle was marked. PDK phosphorylates and inactivates pyruvate dehydrogenase complex that catalyzes irreversible decarboxylation of pyruvate to acetyl-CoA. Inactivation of the complex limits oxidation of glucose and three-carbon compounds to maintain blood glucose levels and promotes fatty acid oxidation. Rapid, efficient and general induction of the mRNA by fibrates at the whole body level suggested a metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates. 9) That is, fibrates rapidly induce transcriptional activation of the PDK4 gene in various tissues, and this is the first step in the action of these agents. Inactivation of pyruvate dehydrogenase by the induced PDK is followed by metabolic switching to limit oxidative fuel to fatty acids apparently similar to the starved condition, although fibrates decrease the serum level of fatty acids in contrast to the state of starvation where the level increases. Enhanced fatty acid utilization is further accelerated by the induction of enzymes involved in fatty acid utilization and repression of apoCIII.
We previously reported that fibrates rapidly induce pyruvate dehydrogenase kinase 4 (PDK4) mRNA in various tissues of mice. 9) Among the tissues examined, the induction of the mRNA in the skeletal muscle was marked. PDK phosphorylates and inactivates pyruvate dehydrogenase complex that catalyzes irreversible decarboxylation of pyruvate to acetyl-CoA. Inactivation of the complex limits oxidation of glucose and three-carbon compounds to maintain blood glucose levels and promotes fatty acid oxidation. Rapid, efficient and general induction of the mRNA by fibrates at the whole body level suggested a metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates. 9) That is, fibrates rapidly induce transcriptional activation of the PDK4 gene in various tissues, and this is the first step in the action of these agents. Inactivation of pyruvate dehydrogenase by the induced PDK is followed by metabolic switching to limit oxidative fuel to fatty acids apparently similar to the starved condition, although fibrates decrease the serum level of fatty acids in contrast to the state of starvation where the level increases. Enhanced fatty acid utilization is further accelerated by the induction of enzymes involved in fatty acid utilization and repression of apoCIII. 10) The model predicts that the muscle will be forced to use amino acids from proteins as an energy source if the metabolic switching and fibrate-induced decreased availability of triglycerides and fatty acids last long. Extensive protein degradation will damage the muscle if the situation is stringent, leading to acute myopathy or rhabdomyolysis. 9) In this study, we tested the hypothesis that induction of PDK4 to limit the oxidation fuel to fatty acid is a potential cause of muscle damage if the availability of fatty acids is limited by hypolipidemic drugs by examining whether the drugs with the risk of rhabdomyolysis, each alone or in combination, further induce PDK4 mRNA in mouse tissues and cultured cells.
MATERALS AND METHODS

Materials
Wy14,643 (4-chloro-6-(2,3-xylidino)2-pyrimidinyl-thio)acetic acid), clofibrate (2-(p-chlorophenoxy)isobutyric acid ethyl ester), DEHA (di(2-ethylhexyl)adipate), and DEHP (di(2-ethylhexyl)phthalate) were purchased from Tokyo-Kasei (Tokyo, Japan) and bezafibrate was from Sigma (St. Louis, U.S.A.). Troglitazone was from Sankyo (Tokyo, Japan). KOD polymerase and restriction enzymes were obtained from Toyobo (Osaka, Japan). [a-32 P]dCTP (3000 Ci/mmol) and a random primer labeling kit were purchased from Muromachi Kagaku (Tokyo, Japan) and Takara (Osaka, Japan), respectively.
Drugs, Doses and Preparation of the Experimantal Diet for Mice Statins and new quinolon anti-bacterial drugs were obtained as tablets of clinical use for patients. The drugs studied were pravastatin as Mevalotin (Sankyo, Japan), simvastatin as Lipovas (Banyu, Japan), atorvastatin as Lipitor (Yamanouchi, Japan), ofloxacin as Tarivid (Daiichi, Japan), norfloxacin as Baccidal (Kyorin, Japan), levofloxacin as Cravit (Dai-ichi, Japan), and bezafibrate as Bezatol (Kissei, Japan). The tablets were powdered and the chemicals of interest were extracted into ethanol or dimethylsulfoxide by sonication. The mixtures were centrifuged and the supernatants were used as stock solutions. The efficiency of extraction and purity of the chemicals were not determined. However, bezafibarte and the extracted material from Bezatol TM gave essentially the same results, suggesting that the method used in this study was appropriate for its purpose. The diet contaning a drug was prepared by absorbing the extracted chemical after dilution with ethanol and the solvent was evaporated at room temperature for 2 d.
Animals and Treatment Normal male C57BL mice (5-6 weeks old) were kept under a 12 h light-dark cycle and provided with food and water ad libitum. Mice were fed either a control diet (CE7, Clea, Japan) or that containing a drug at the concentration described in Table 1 for the periods indicated in the figure legends. The amounts of diet fed to mice were not significantly different among the drugs used. Mice in the anesthetized condition were killed by exsanguination (approved by the Meiji Pharmaceutical University Committee for Ethics of Experimentation and Animal Care) for tissue preparation.
Cell Culture Fao cells, a subclone of rat hepatoma HIIE cells, were cultured in Ham's F12 medium under the conditions reported previously.
11) C2C12 myoblasts were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% L-glutamine. Differentiation of C2C12 myoblasts into myotubes was induced by changing to medium containing insulin.
RNA Preparation and Northern Blotting Total RNA was prepared from the mouse tissues and cultured cells by the acid guanidinium isothiocyanate-phenol-chloroform extraction method. 12) Northern blotting analysis was carried out essentially as described previously using Express Hyb TM hybridization solution (Clontech, U.S.A.) at 68°C for 3 h. 13) After hybridization, the membranes were washed and autoradiographed with an intensifying screen at Ϫ80°C. For quantitative analysis, a BAS2000 image analyzer (Fujix, Japan) was used. The cDNAs used as probes for hybridization were obtained by cloning PCR products of cDNA synthesized from poly(A) RNA purified from the livers of Wy14,643-fed mice. Their identities were confirmed by sequencing and the cDNA probes were prepared by PCR of the plasmid DNAs as described previously. 11, 13) 
RESULTS
Rapid Induction of PDK4 mRNA by Various Fibrates
To examine whether PDK4 mRNA expression is induced only by Wy14,643 or this is a general effect of fibrates or any other peroxisome proliferators, the effects of several compounds were studied using mice and cultured hepatoma cells. Total RNA was prepared from the livers of mice or the cells after treatment and analyzed by Northern blotting (Fig. 1A) . Induction of the mRNA in the mouse liver after 6 h of feeding the diet containing the drug was also observed with bezafibrate and clofibrate but not by other peroxisome proliferators, DEHA and DEHP. 11) This specificity was in marked contrast to the responses of the metallotheionein I 14) and serum amyloid A 15) mRNAs that were induced and repressed, respectively, by all the drugs tested. The more rapid induction of PDK4 mRNA by fibrates than those of peroxisomal HD (hydratase-dehydrogenase) and thiolase mRNAs 9) was confirmed in this experiment by Northern blotting. In the hepatoma cells, it was confirmed that another fibrate, ciprofibrate, 11) efficiently induced PDK4 mRNA and the PPAR (peroxisome proliferator-activated receptor) g ligand troglitazone had no effect on this induction (Fig. 1B) . Thus, it was suggested that PDK4 mRNA is induced rapidly and specifically by various fibrates in the liver and hepatoma cells.
Induction of PDK4 mRNA by Statins and New Quinolon Anti-bacterial Drugs in Mouse Tissues
To examine whether the drugs that were reported to cause rhabdomyolysis 6, 7, 17) induce PDK4 mRNA in the liver and muscle, the mice were fed a diet containing each drug for 2 d and the levels of the mRNA were determined by Northern blotting (Fig. 2) . The doses of the drugs were chosen by considering the case of bezafibrate; the drug is prescribed for patients at a dose of 400 mg per day in Japan and it is usually used at 0.2% in the experimental diet for mice and at 200 mM for cell culture studies. 13) Other clinical drugs were used at concentrations in proportion to that of bezafibrate as summarized in Table 1 .
In the liver, only bezafibrate induced PDK4 mRNA similar to PPARa-regulated mRNAs and repressed PEPCK (cytosolic phosphoenolpyruvate carboxykinase) mRNA. In contrast, two new quinolon anti-bacterial drugs, ofloxacin and norfloxacin, in addition to bezafibrate, efficiently induced PDK4 mRNA in the muscle. In addition, simvastatin less efficiently but significantly induced the mRNA. It is noteworthy that all these drugs also induced all the PPARa-regulated mRNAs (CTE (cytosolic thioesterase I), FATP1 (fatty acid transport protein 1), FAT (fatty acid translocase)/CD36, H-FABP (heart-type fatty acid binding protein) and LACS (long chain acyl-CoA synthase)) in the muscle. In the kidney, the mRNAs responded similar to that in the liver. Thus, the relationship between the receptor PPARa and the agonists may not be absolute but dependent on the type of tissues. Several, but not all, of statins and new quinolon anti-bacterial drugs tissue-specifically induced PDK4 mRNA in the muscle. To examine whether the efficient induction of PDK4 mRNA in the liver and muscle could be reproduced in the cultured cells, rat hepatoma Fao cells and mouse myotubes differentiated from myoblast C2C12 cells were treated with low and high concentrations of several drugs and the changes in the levels of mRNAs as above were analyzed by Northern blotting (Fig. 3) . High concentrations of pravastatin and ofloxacin were toxic to the hepatoma cells as evidenced by degradation of total RNA. In both cells, only bezafibrate efficiently induced PDK4 mRNA. Bezafibrate, either from the tablets or pure chemical reagent, showed the same result, suggesting that the extraction method described in Experimental Procedures was suited for our purpose. Only simvastatin slightly induced PDK4 mRNA and also two PPARaregulated mRNAs, HD and LACS, 11, 17) in the hepatoma cells but not muscle cells. Norfloxacin was an efficient inducer of the PDK4 mRNA in the muscle (Fig. 2) but did not influence the mRNA level in the cells. No other drugs showed an effect on the expression of the mRNAs examined. These results indicated that the mechanisms for induction of PDK4 mRNA by fibrate and that by statins or new quinolon anti-bacterial drugs are not exactly the same.
Inefficient Induction of PDK4 mRNA by Statins and New Quinolon Anti-bacterial Drugs in the Cultured Cells
Synergistic Effect of Fibrates and Statins on the Induction of PDK4 mRNA Since it is known that the risk of rhabdomyolysis increases with combination therapy using fibrate and statin, 5, 6) we next examined the effect of bezafibrate together with a statin, pravastatin or simvastatin, on the expression of PDK4 mRNA in the liver and muscles of mice. A higher dose of bezafibrate (2%) gave a result similar to that with a lower dose (0.3%) on the expression levels of PDK4 Table 1 ) of the drug indicated for 24 h. The drugs used were; Pra, pravastatin; Sim, simvastatin; Ofl, ofloxacin; Bez, bezafibrate from Bezatol; Nor, norfloxacin; Lev, levofloxacin; bez, bezafibrate of reagent grade. (B) Differentiated C2C12 cells were treated with the drugs as above. From both cells, total RNA (5 mg) was prepared and subjected to Northern blotting analysis using cDNA probes as indicated. Samples for mouse muscle fed either a control diet (Ϫ) or that containing bezafibarate (bez) for 2 d were also analyzed with those from C2C12 cells. and other PPAR target gene transcripts both in the liver and muscle, suggesting that the PPAR was fully activated by the fibrate in both tissues. However, the addition of a statin further increased the expression level of PDK4 mRNA in these tissues. In contrast to PDK4 mRNA, LACS and HD mRNAs were not further induced by a statin. These results suggested that the effects of fibrate and statin on the expression level of PDK4 mRNA were synergistic and the modes of action were different from each other.
Liver-Specific Responses of Branched-Chain a a-Keto Acid Dehydrogenase Kinase mRNA Expression to the Drugs To examine the effect of fibrates, statins and new quinolon anti-bacterial drugs on the essential amino acid catabolism, the changes in the levels of the mRNA for branched-chain a-keto acid dehydrogenase kinase (BDK) were measured by Northern blotting. BDK phosphorylates and inactivates the rate limiting enzyme branched chain aketo acid dehydrogenase to conserve the essential amino acids.
18) The expression levels of BDK mRNA under normal conditions were low in the liver and high in the kidney and muscle presumably because the laboratory diet was a highprotein diet. Responses of the BDK gene expression to the drugs were different between the liver and the muscle; BDK mRNA in the liver increased by the same drugs solely and in combination as in the case of PDK4 mRNA, whereas the levels of BDK mRNA in the muscle did not change at all under various conditions. These results suggested that the mechanism to conserve the essential amino acids was started by the drugs in the liver but not in the muscle.
DISCUSSION
Fibrates rapidly and efficiently induce PDK4 in various tissues including skeletal muscle. Inactivation of pyruvate dehydrogenase by the induced PDK switches the metabolism to limit oxidation fuel to fatty acids. Our metabolic switching hypothesis 9) claims that this is the first step in the hypolidemic effects of fibrates, followed by induction of enzymes for fatty acid utilization. Thus, the hypolipidemic drugs rapidly reduce the serum levels of triglycerides and fatty acids. It is noteworthy that the induction of PDK4 mRNA is rapid but transient in contrast to that of mRNAs for fatty acid utilizing enzymes. So, the conditions to limit the energy source to fatty acids do not last long and the muscle will not be cornered to use amino acids from proteins as an energy source. However, our fibrate-induced metabolic switching hypothesis predicts that the more extensive and the longer the period PDK4 is induced by another type of drug in combination with fibrates, the more severely protein degradation occurs in the muscle.
The present study demonstrated that several statins and new quinolon anti-bacterial drugs solely induced PDK4 mRNA as efficiently as fibrates in the mouse muscle but far less efficiently in the liver and kidney (Fig. 2) . There may be little correlation between the physicochemical properties (hydrophobicities) of the drugs 8) and the efficiencies of the induction in the myocyte because a relatively hydrophilic statin, pravastatin, efficiently induced the mRNA. Furthermore, combination treatment with a fibrate, bezafibrate, and a statin, pravastatin or simvastatin, synergistically induced PDK4 mRNA in the muscle similar to that in the liver of mice (Fig. 4) . In contrast, BDK mRNA was induced by the drugs in the liver but not in the muscle, suggesting that the muscle could not conserve the essential amino acids after protein degradation. These results of combination treatment agree with those of clinical studies showing that the incidence of myopathy is in the range of 0.1-0.5% with monotherapy, increasing to 0.5-2.5% with combination therapy. 6) The statins and new quinolon anti-bacterial drugs indirectly activated PPARa in a tissue-specific manner, but the effects of these drugs were not to increase the concentrations of the ligands because low and high concentrations of bezafibrate alone gave the same results but the statins further increased the expression of PDK4 mRNA. In this context, it is interesting that human studies to assess the effects of bezafibrate and gemfibrozil on the pharmacokinetics of lovastin showed that gemfibrozil markedly increased the plasma concentrations of lovastatin, but bezafibrate did not. 19) There may be differences between individual fibrates and also between individual statins, 20) and also we must consider the species differences. Statins and fibrates may interact at the level of pharmacokinetics, or at some step in transcriptional modulation. Martin et al. reported that statin-induced reduction of geranylgeranyl phosphate inhibits the kinase cascade to phosphorylate and inactivate PPARa, thus statins activate PPARa in a synergistic manner with fibrates. 21) However, a 
B
synergistic effect of fibrates and statins was observed only in the expression of PDK4 and CTE but not typical PPARa-target genes such as HD and LACS. Furthermore, a fibrate-induced repression of PEPCK in the liver was reversed by the addition of statins (Fig. 4) , and an efficient effect of statins was observed only in the mouse muscle but not in the liver, or cultured cells (Figs. 1, 2) . In addition to the above proposed mechanism, other mechanisms including tissue-specific ones, that are not fully reproduced in the cultured cells, may be required to explain the synergistic effect of fibrates and statins on the gene expression of several genes in the mouse tissues.
Induction of PDK4 mRNA under the conditions of starvation is an adaptive mechanism to maintain blood glucose levels, 22) as supported by an example of concomitant induction of the mRNA for PEPCK, a key enzyme in gluconeogenesis (Figs. 2A, 4A ). In contrast, PDK4 mRNA was induced by fibrates and statins in the liver but not by starvation, although it was induced by both in muscles. PEPCK mRNA was repressed by fibrates but was induced by starvation in the liver ( Fig. 2A) . The serum levels of fatty acids increase during starvation, but fibrates reduced the levels of triglycerides and fatty acids. Thus, the mechanism to induce PDK4 mRNA in the mouse tissues by fibrates and statins may not be the same as that under the conditions of starvation. Sugden et al. reported that the renal PDK4 protein level was markedly increased in wild-type mice but was induced only marginally in PPARa-null mice by starvation. 22) Holness et al. also reported that starvation-induced PDK4 expression in the oxidative muscle did not necessarily require PPARa. 23, 24) Whether PPARa is directly required or not for the fibrate and statininduced expression of PDK4 is crucial to elucidate the molecular mechanism.
Synergistic induction of PDK4 by fibrates and statins without induction of the conservation system for the essential amino acids in the muscle can be a cause of acute rhabdomyolysis because fibrates reduce a limited energy source, triglycerides and fatty acids in serum. The effect of fibrate to reduce the serum triglycerides and fatty acids are chronic, whereas the time course of PDK4 induction is rapid and transient. 9) So, the duration of the conditions to induce acute rhabdomyolysis may be limited to the early stage of the combination treatment with fibrates and statins, and this prediction is supported by findings of previous clinical studies. 6) To avoid fibrate and statin-induced rhabdomyolysis, it will be important to improve the time schedule of medication and the doses of the drugs, in addition to elucidating the mechanism of the PDK4 induction in the muscle.
